Lastly, CAR T-cell immunotherapy targeting B7-H3 in HCC is under investigation by a phase I/II trial, in combination with fludarabine and cyclophosphamide (NCT05323201), and for hepatoblastoma in two phase I trials (NCT04897321, NCT04483778). This evidence concerns the gene CD276 and hepatocellular carcinoma.